Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors

نویسندگان

  • Moritz Schütte
  • Thomas Risch
  • Nilofar Abdavi-Azar
  • Karsten Boehnke
  • Dirk Schumacher
  • Marlen Keil
  • Reha Yildiriman
  • Christine Jandrasits
  • Tatiana Borodina
  • Vyacheslav Amstislavskiy
  • Catherine L Worth
  • Caroline Schweiger
  • Sandra Liebs
  • Martin Lange
  • Hans-Jörg Warnatz
  • Lee M Butcher
  • James E Barrett
  • Marc Sultan
  • Christoph Wierling
  • Nicole Golob-Schwarzl
  • Sigurd Lax
  • Stefan Uranitsch
  • Michael Becker
  • Yvonne Welte
  • Joseph Lewis Regan
  • Maxine Silvestrov
  • Inge Kehler
  • Alberto Fusi
  • Thomas Kessler
  • Ralf Herwig
  • Ulf Landegren
  • Dirk Wienke
  • Mats Nilsson
  • Juan A Velasco
  • Pilar Garin-Chesa
  • Christoph Reinhard
  • Stephan Beck
  • Reinhold Schäfer
  • Christian R A Regenbrecht
  • David Henderson
  • Bodo Lange
  • Johannes Haybaeck
  • Ulrich Keilholz
  • Jens Hoffmann
  • Hans Lehrach
  • Marie-Laure Yaspo
چکیده

Colorectal carcinoma represents a heterogeneous entity, with only a fraction of the tumours responding to available therapies, requiring a better molecular understanding of the disease in precision oncology. To address this challenge, the OncoTrack consortium recruited 106 CRC patients (stages I-IV) and developed a pre-clinical platform generating a compendium of drug sensitivity data totalling >4,000 assays testing 16 clinical drugs on patient-derived in vivo and in vitro models. This large biobank of 106 tumours, 35 organoids and 59 xenografts, with extensive omics data comparing donor tumours and derived models provides a resource for advancing our understanding of CRC. Models recapitulate many of the genetic and transcriptomic features of the donors, but defined less complex molecular sub-groups because of the loss of human stroma. Linking molecular profiles with drug sensitivity patterns identifies novel biomarkers, including a signature outperforming RAS/RAF mutations in predicting sensitivity to the EGFR inhibitor cetuximab.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Role of Molecular Biomarkers in Colorectal Cancer

Colorectal cancer (CRC) is amongst the most widespread cancers and is a most common cause of cancer associated mortality universally. Since previous decades, it has been cleared that CRC develops owing to the buildup of a series of genetic and epigenetic changes in the normal colonic epithelium. Regardless of the current development in surgery and therapies, overall survival of end stage CRC pa...

متن کامل

Comparison of Four Data Mining Algorithms for Predicting Colorectal Cancer Risk

Background and Objective: Colorectal cancer (CRC) is one of the most prevalent malignancies in the world. The early detection of CRC is not only a simple process, but it is also the key to its treatment. Given that data mining algorithms could be potentially useful in cancer prognosis, diagnosis, and treatment, the main focus of this study is to measure the performance of some data mining class...

متن کامل

Epigenetics in diagnosis of colorectal cancer

Colorectal cancer (CRC) is a third most common epithelial carcinoma. CRC is known to develop from the early precancerous lesion to full blown malignancy via definite phases due to cumulative mutations and aberrant methylation of number of genes. The use of serum biomarkers that is non-invasive to discriminate cancer patients from healthy persons will prove to be an important tool to improve the...

متن کامل

Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients.

PURPOSE KRAS wild-type status is an imperfect predictor of sensitivity to anti-EGF receptor (EGFR) monoclonal antibodies in colorectal cancer, motivating efforts to identify novel molecular aberrations driving RAS. This study aimed to build a quantitative readout of RAS pathway activity to (i) uncover molecular surrogates of RAS activity specific to colorectal cancer, (ii) improve the predictio...

متن کامل

Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer

The monoclonal antibodies panitumumab and cetuximab that target the epidermal growth factor receptor (EGFR) have expanded the range of treatment options for metastatic colorectal cancer. Initial evaluation of these agents as monotherapy in patients with EGFR-expressing chemotherapy-refractory tumors yielded response rates of approximately 10%. The realization that detection of positive EGFR exp...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 8  شماره 

صفحات  -

تاریخ انتشار 2017